NES and breast carcinoma: In agreement of the aforementioned recent study observations by Dusart et al. [15], our study found a significantly lower serum Nestin values in breast cancer group compared to the control group, with a cut-off of 39.9 pg/mL representing the best value for discriminating patients with breast cancer from normal women, where, lower Nestin values were found to be associated with increased probability to cancer.